Róbert Wessman

Petar Vazharov is the Chief Executive Officer of Lotus and responsible for leading Lotus's management and business expansion, and strategic execution.

Mr. Vazharov has over 30 years of Pharma industry experience. He spent nine years with the generic pharmaceutical company Actavis Group in various roles and has demonstrated his ability to lead the CEE business. In 2020, he started to lead Lotus to expand its global business and formulate a complete market strategy to achieve long-term and stable growth goals.

After the deal that Aztiq and Innobic became the main shareholders of Lotus, Petar said: "We are so excited to kick off another new chapter of Lotus's journey with the combined efforts from industry veteran and regional leader. Lotus has achieved several major milestones and is now the largest generic company in Taiwan. Again, this transaction is a testimonial for all the achievements Lotus has made during the past few years and great recognition by these two long-term partners for Lotus. Innobic and Aztiq will support Lotus's existing strategy and fuel the growth by bringing new opportunities, experience, and resources."

Petar graduated with a medical doctor's degree from Sofia University of Medicine in 1999 and has an MBA degree from the University of Sofia "Kliment Ohridski" in October 2007.

Petar Vazharov

Ms. Krisana Winitthumkul is Director at Innobic (Asia) and, working closely with Thai Health Authorities and associations to drive the change in regulatory requirements, actively participate in ASEAN Harmonization for Pharmaceutical Registration. She also involves in monitoring the external environment, which impacts the healthcare industry, and strengthens collaboration and regulatory reform activities in the Thai Health System.

Ms. Krisana has more than 30 years of experience in the pharmaceutical industry. She was the Regulatory Affairs and Quality Assurance Lead of Roche Thailand Ltd and worked at other big pharma in charge of regulatory affairs. In addition, she has served as the Vice President of the Regulatory Affairs Pharmaceutical Association of Thailand (RAPAT) for a long time, accumulating rich experience in regulations.

Ms. Krisana obtained her Bachelor's degree in Pharmacy from Chiang Mai University, Thailand, and her Certificate from Sasin Executive Education Center.

KrisanaWinitthumkul

Ms. Phannalin Mahawongtikul joined Lotus’ Board of Directors on June 30th, 2022. She is the Chief Financial Officer of PTT Public Company Ltd. and is also a member of the Risk Management Committee at Thai Oil Public Company Ltd.

Ms. Phannalin obtained both her MBA and Bachelor of Accounting from Thammasat University.

Phannalin Mahawongtikul

Ms. Oranee Tangphao-Daniels joined Lotus’ Board of Directors on June 30th, 2022. Ms. Oranee has more than 30 years in the pharma industry. She worked for Eli Lilly as a Clinical Pharmacologist/Clinical Research Physician and Amgen as Director to Executive Director. She is now the Chief Medical Officer at Antiva Biosciences, a novel topical therapies development company focusing on pre-cancerous lesions caused by HPV.

Ms. Oranee holds a Master’s degree in Cardiovascular Pharmacology from Mc Master University and graduated from Chulalongkorn University with a Bachelor of Medicine (Internal Medicine). She was a Post-Dec then Research Associate at Standford University from 1994 to 2000.

Oranee Tangphao-Daniels, MD

Nat joined the Board of Directors of Lotus on September 4th,2023. Currently, Nat serves as the Managing Director at Innobic (Asia) Company Limited and the Executive Vice President of PTT Public Company Limited. Nat possesses a Ph.D. degree in civil engineering from the University of Texas at Austin and has rich experience in project management in the oil, gas, and petrochemical business. Recently, Nat has played a critical role in PTT’s business expansion into the area of life science.

Nat Ativitavas

Mr. Yves Hermes joined Lotus’ Board of Directors on June 30th, 2022. He worked at SGS Asia Pacific as a Financial Analyst and became Managing Director for SGS Korea and Japan from 2000-2005. Mr. Hermes was then heading Zuellig Pharma Taiwan, Thailand, and serving as Area Director for Southeast Asia at Zuellig Pharma International Services before he founded his own company – Yves Hermes Healthcare Consultancy, in 2021.

Mr. Hermes graduated from the University of Geneva, Switzerland, and obtained a Bachelor of Economics and Finance.

Yves Hermes

Árni Hardarson is a director on Alvotech´s and Alvogen’s Board of Directors as well as being a Co Chairman of Aztiq.

Prior to joining Alvogen in 2009, Árni worked for Deloitte in Iceland where he headed the Tax and Legal departments and soon went on to become a partner and member of the Executive Management Committee for Deloitte in 2001.

In 2005 Árni joined Actavis as Vice President of Tax and Structure. During his tenure there, he worked closely with Róbert Wessman and contributed to Actavis’ transformation from a regional manufacturer into a global pharmaceutical company, by engineering numerous company acquisitions that ultimately led to Actavis’ presence in over 40 countries around the world.

Árni holds a Master’s degree in Law from the University of Iceland and is a member of the Icelandic Bar Association.

Árni Hardarson

Mr. Palsson joined Lotus’s Board of Directors on April 23rd, 2015. He currently serves as independent non-executive Board member and Business Consultant in various different sectors, including financial, pharmaceuticals, telecommunications and non-profits organizations across the world. Mr. Palsson is also the Chairman of Lotus’s Audit Committee.

Mr. Palsson was EVP and CFO of a leading medical device company, listed on NASDAQ OMX Copenhagen, from 2001 to 2013. He gained comprehensive experience in leading Accounting, Planning, Investor Relations, Financing, Corporate M&A, Human Resources and Business Information Services there. Prior to that, Mr. Palsson was a partner and a Board member at Deloitte & Touche in Iceland where he practiced as a State Authorized Public Accountant. 

Hjorleifur Palsson

Ms. Jennifer Wang joined Lotus’s Board of Directors as an independent director on June 15th, 2023.

Ms. Wang is currently a partner lawyer in Chen & Lin Attorneys-at-Law. She has more than 20 years of professional experience in legal services to clients in different industry categories. She has also served as an independent Director of TXC Corporation since 2016.

Ms. Wang graduated from National Taiwan University with a master’s degree in law. She studied corporate, securities and mergers and acquisitions at Columbia Law School in 2002. She obtained her second master’s degree in law and passed the New York Bar Examination in 2003.

Jennifer Wang

Mr. Karl Karlsson joined Lotus’s Board of Directors as an independent director on June 15th, 2023.

Mr. Karlsson has nearly 20 years in the pharma industry. He worked for Bluefish Pharmaceuticals as a founder, Chief Executive Officer, and Board Member. He is currently the founder and Executive Chairman of Newbury Pharmaceuticals AB, a rapidly growing hybrid pharmaceutical company for specialty prescription drugs, innovation, and brands with focus on the Scandinavian markets.

Mr. Karlsson studied marketing and business administration at George Mason University and has an MBA degree from Harvard Business School in 2013.

Karl Karlsson

Lotus’s Board of Directors consists of eleven distinguished members with exceptional knowledge and experience in related fields, with a balanced diversity of professions, experiences, as well as gender. Three out of eleven directors are independent directors and perform their duties in accordance with the Company’s Articles of Incorporation and relevant bylaws to protect the interests of all shareholders.

The Board of Directors supervises the Company’s operation and compliance with relevant laws and regulations and guides the Company’s management team to maximize shareholders' value in the long run. The Board of Directors is also responsible for evaluating the management team’s performance and ensuring the team runs the business operations disciplined and prudently.